Low molecular weight heparin for the prevention of deep venous thrombosis: a suitable monitoring in elderly patients?
作者： Isabelle Mahé , Ludovic Drouet , Olivier Chassany , Anne-Sophie Grenard , Charles Caulin
DOI: 10.1159/000065216
关键词:
摘要: Monitoring of anti-Xa activity (aXa) levels is not routinely required in patients receiving enoxaparine at prophylactic dosages, since aXa supposed to stay below the manufacturer’s recommended rang
sci-hub.se 参考文章(14)
P. Mismetti, S. Laporte-Simitsidis, C. Navarro, P. Sié, P. d’Azemar, J. Necciari, J. P. Duret, C. Gaud, H. Decousus, B. Boneu, Aging and Venous Thromboembolism Influence the Pharmacodynamics of the Anti-Factor Xa and Anti-thrombin Activities of a Low Molecular Weight Heparin (Nadroparin) Thrombosis and Haemostasis. ,vol. 79, pp. 1162- 1165 ,(1998) , 10.1055/S-0037-1615034
F Collignon, A Frydman, H Caplain, M L Ozoux, Y Le Roux, J Bouthier, J J Thébault, Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thrombosis and Haemostasis. ,vol. 73, pp. 630- 640 ,(1995) , 10.1055/S-0038-1653833
Meyer Samama, Anthonie Lensing, Harry Büller, Jeanne Barre, Nicole Vochelle, Bertrand Beau, André Planès, Prevention of Deep Vein Thrombosis after Hip Replacement Thrombosis and Haemostasis. ,vol. 81, pp. 22- 25 ,(1999) , 10.1055/S-0037-1614411
Jack Hirsh, Theodore E. Warkentin, Stephen G. Shaughnessy, Sonia S. Anand, Jonathan L. Halperin, Robert Raschke, Christopher Granger, E. Magnus Ohman, James E. Dalen, Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety Chest. ,vol. 119, pp. 64- ,(2001) , 10.1378/CHEST.119.1_SUPPL.64S
Mark D. Shaieb, Brandi N. Watson, Robert E. Atkinson, Bleeding complications with enoxaparin for deep venous thrombosis prophylaxis. Journal of Arthroplasty. ,vol. 14, pp. 432- 438 ,(1999) , 10.1016/S0883-5403(99)90098-0
C.Seth Landefeld, E.Francis Cook, Margaret Flatley, Monica Weisberg, Lee Goldman, Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy The American Journal of Medicine. ,vol. 82, pp. 703- 713 ,(1987) , 10.1016/0002-9343(87)90004-0
Norman RC Campbell, Russell D Hull, Rollin Brant, David B Hogan, Graham F Pineo, Gary E Raskob, Aging and Heparin-Related Bleeding Archives of Internal Medicine. ,vol. 156, pp. 857- 860 ,(1996) , 10.1001/ARCHINTE.1996.00440080047006
Bernard Boneu, Philippe de Moerloose, How and when to monitor a patient treated with low molecular weight heparin. Seminars in Thrombosis and Hemostasis. ,vol. 27, pp. 519- 522 ,(2001) , 10.1055/S-2001-17961
P.A. Ockelford, C.J. Carter, L. Mitchell, J. Hirsh, Discordance between the anti-Xa-activity and the antithrombotic activity of an ultra low molecular weight heparin fraction Thrombosis Research. ,vol. 28, pp. 401- 409 ,(1982) , 10.1016/0049-3848(82)90121-9
Steven H. Stern, Richard L. Wixson, Daryl O'Connor, Evaluation of the safety and efficacy of enoxaparin and warfarin for prevention of deep vein thrombosis after total knee arthroplasty. Journal of Arthroplasty. ,vol. 15, pp. 153- 158 ,(1998) , 10.1016/S0883-5403(00)90066-4